Company profile: Forma Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical discovery, development and commercialization of transformative medicines leveraging biology and chemistry to address genomically validated cancer drivers; haemophilia A prophylaxis with Mim8 and the FRONTIER clinical programme; diabetes care for children; low-cost insulin access; humanitarian health partnerships; and haemophilia care support via a dedicated foundation.
Products and services
- FRONTIER Programme: A clinical development programme assessing Mim8 for prophylaxis in haemophilia A through multiple phase 3 trials across different age groups and treatment comparisons
- Mim8: A next-generation FVIIIa mimetic bispecific antibody that delivers once-weekly or once-monthly prophylaxis in haemophilia A, suitable for patients with or without inhibitors
- Access to Insulin Commitment: A pledge to supply low-cost human insulin in low- and middle-income countries, ensuring affordability and availability for vulnerable populations
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Forma Therapeutics
Qiagen
HQ: The Netherlands
Website
- Description: Provider of technologies and products for preanalytical sample preparation and linked molecular assay solutions. Supplies diagnostic kits, tests, and assays for human and veterinary molecular diagnostics, with sample and assay consumables offered in kit form. Portfolio includes automated nucleic acid purification systems, sample disruption tools, real-time and digital PCR platforms, and automated PCR setup.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qiagen company profile →
Clear Labs
HQ: United States
Website
- Description: Provider of biotechnology solutions that integrate a genomics system to simplify diagnostics for the clinical and application sectors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clear Labs company profile →
Synlab
HQ: Germany
Website
- Description: Provider of laboratory diagnostics for human and veterinary medicine and environmental analysis services. Delivers wide-ranging laboratory testing, specialty and genetic testing (including preimplantation), supported by 2,000+ medical experts across 30+ countries and 2,000+ blood collection points. Also focuses on medical supplies trade, clinical trials, and consulting.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synlab company profile →
GenSight Biologics
HQ: France
Website
- Description: Provider of gene therapy-based treatments for retinal degenerative diseases. Develops candidates such as GS010 (lenadogene nolparvovec) for Leber Hereditary Optic Neuropathy (LHON) and GS030, an optogenetics-based therapy in Phase I/II trials, leveraging mitochondrial targeting sequence (MTS) technology and optogenetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GenSight Biologics company profile →
Delfi Diagnostics
HQ: United States
Website
- Description: Provider of high-precision, non-invasive blood tests for early cancer detection, including the FirstLook Lung test using DNA fragment patterns; leverages machine learning and fragmentomics to analyze cell-free DNA fragments; and runs the CASCADE-LUNG clinical study to validate blood-based lung cancer screening technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delfi Diagnostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Forma Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Forma Therapeutics
2.2 - Growth funds investing in similar companies to Forma Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Forma Therapeutics
4.2 - Public trading comparable groups for Forma Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →